HOECHST ALLEGES COGNEX INFRINGEMENT OF PATENT
Executive Summary
HOECHST ALLEGES COGNEX INFRINGEMENT OF PATENT in a suit filed Sept. 30 in Wilmington, Del. federal court. Hoechst-Roussel Pharmaceuticals is charging Warner-Lambert with infringing a composition and use patent (#4,631,286) for a class of compounds called acridines, patented as "useful in the treatment of various memory dysfunctions characterized by decreased cholinergic function, such as Alzheimer's disease." Acridines are also patented as having utility "to inhibit the enzyme cholinesterase and thereby increase acetylcholine levels in the brain." The "286 patent was filed Oct. 25, 1984 and issued to Hoechst in Dec. 23, 1986. The inventors are Gregory Shutske and Frank Pieffat. Warner-Lambert began shipping the cholinesterase inhibitor Cognex (tacrine) at the end of September after receiving FDA approval Sept. 9 for the treatment of patients with "mild to moderate dementia of the Alzheimer's type" ("The Pink Sheet" Sept. 13, p. 6). Cognex labeling notes that it "presumably acts by elevating acetylcholine released by the still intact cholinergic neurons." Warner-Lambert described the Hoechst suit as without merit. Hoechst is completing studies of its potential Alzheimer's treatment, Mentane (voinacrine) that were requested by FDA's Peripheral & Central Nervous System Drugs Advisory Committee last November after the committee denied the company's Treatment IND request. Hoechst had filed the Mentane NDA five months before the advisory committee meeting based on one pivotal trial and interim results from an ongoing study ("The Pink Sheet" Nov. 9, 1992, p. 5). The Hoechst patent claims that its acridine compounds are "in general less toxic" than tacrine and some of the compounds "exhibit antidepressant activities, which activities being particularly helpful for patients suffering from Alzheimer's disease." The discussion of antidepressant activities in the patent might be an indication of a possible Hoechst strategy for differentiating Mentane from Cognex in a clinical and/or marketing context. The lawsuit seeks preliminary and permanent injunctions to prevent further infringement of the patent and treble damages. Attorneys William Wade and Thomas Beck of the Wilmington law firm, Richards, Layton & Finger, are representing Hoechst. Of counsel are Herbert Schwartz and Kenneth Herman of the New York City firm Fish & Neave.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth